Tokyo

London

New York

finscreener facebook fan page

finscreener twitter page

Register

Sign In

FinScreener

EUR/USD

1.1994

0.0038

0.32%

GBP/USD

1.3512

-0.0000

-0.00%

USD/JPY

111.58

0.0920

0.08%

USD/CHF

0.9626

0.0008

0.09%

EUR/GBP

0.8877

0.0028

0.32%

USD/CAD

1.2290

0.0010

0.09%

NZD/USD

0.7317

0.0058

0.80%

EUR/JPY

133.83

0.5290

0.40%

EUR/CHF

1.1545

0.0046

0.40%

Aclaris Therapts Cmn

NASDAQ: ACRSHealthcare / Biotechnology / USA
25.29-0.06-0.24%Vol 355 9901Y Perf 6.26%
Sep 19th, 2017 16:00
BID25.26 ASK25.27
Open25.55 Previous Close25.35
Pre-Market- After-Trading25.27
 - -%  -0.02 -0.08%
Target Price
43.50 
Analyst Rating
Strong Buy 1.00
Potencial %
72.00 
Finscreener Ranking
—    -
Insiders Trans % 3/6/12M
100/100/-50 
Value Ranking
—    -
Insiders Value % 3/6/12M
100/100/-79 
Growth Ranking
—    -
Insiders Shares Cnt. % 3/6/12M
100/100/-75 
Income Ranking
—    -
Market Cap (mil)676 
Earnings Rating
Strong Buy
Price Range Ratio 52wk %
39.24 
Earnings Date
2nd Nov 2017

Today's Price Range

25.1225.97

 

52wk Range

20.1533.25

Summary:

Strong Sell

Technical Indicators: Strong Sell
Moving Averages: Strong Sell
Performance
1 Month
1.56%
3 Months
-0.55%
6 Months
-12.53%
1 Year
6.26%
3 Years
-
5 Years
-
Last Quotes
Name / TickerPriceChg.Chg.%
ACRS25.29-0.0600-0.24
AAPL158.730.06000.04
GOOG921.816.81000.74
MSFT75.440.28000.37
XOM80.220.13000.16
WFC53.360.65001.23
JNJ135.22-0.1600-0.12
FB172.522.51001.48
GE24.20-0.2600-1.06
JPM93.941.02001.10
...

TickerPriceChg.%52 Week High
LUK24.293.9427.33
KORS46.183.4352.67
NRG24.623.2726.25
AA46.202.8746.44
PGR47.632.8549.01
MGM32.562.7834.65
ALB134.652.77135.26
DE123.082.66132.50
NTAP41.712.6645.24
VZ49.342.6054.83
FCX14.482.4817.06
WYNN147.012.20147.50
T38.212.1143.03
Financial StrengthValueIndustryS&P 500US Markets
Quick Ratio 20.40
Current Ratio 21.00
Long Term Debt to Total Capital -
Total Debt to Equity -
Interest Coverage -
Leverage Ratio 1.00
ProfitabilityValueIndustryS&P 500US Markets
Gross Margin-
EBIT Margin-
EBITDA Margin-
Pre-tax Profit Margin-
Profit Margin-
ValuationValueIndustryS&P 500US Markets
PE Ratio -
PB Ratio 4.11
PS Ratios -
Price to Cash Flow -
Price to Free Cash Flow -16.80
Cash Flow Per Share -1.67
Price to Tangible Book4.11
Book Value per Share6.29
Enterprise Value (in ths.)520 107
Management EffectivenessValueIndustryS&P 500US Markets
Return on Equity (5Y Avg)-
ROE last 12 Months -37.99
Return on Assets (5Y Avg) -
ROA last 12 Months -35.96
Return on Capital (5Y Avg) -
ROC last 12 Months -38.37
Return on invested Capital Q -9.04
Return on invested Capital Y-36.70
Assets Turnover0.00
Receivables Turnover-
RevenueValueIndustryS&P 500US Markets
Revenue LTM (in ths.)0
Revenue per Share 0.00
Revenue Growth 3 Years -
Revenue Growth 5 Years -
DividendsValueIndustryS&P 500US Markets
Dividend Yield -
Dividend Rate -
Dividend Growth 3 Years-
Dividend Growth 5 Years-

Earnings HistoryEstimateReportedSurprise %
Q02 2017-0.68-0.5617.65
Q01 2017-0.54-0.4811.11
Q04 2016-0.59-0.4916.95
Q03 2016-0.68-0.5026.47
Q02 2016-0.61-0.62-1.64
Q01 2016-0.50-0.65-30.00
Q04 2015-0.40-0.2830.00
Q03 2015-1.46-5.11-250.00
Earnings Per EndEstimateRevision %Trend
9/2017 QR-0.892.20Positive
12/2017 QR-1.15-2.68Negative
12/2017 FY-3.103.13Positive
12/2018 FY-3.43-0.88Negative
Next Report Date2nd Nov 2017
Estimated EPS Next Report-0.89
Estimates Count3
EPS Growth Next 5 Years %0.00
Volume Overview
Volume355 990
Shares Outstanding (in ths.)26 740
Trades Count1 484
Dollar Volume7 721 736
Avg. Volume277 579
Avg. Weekly Volume404 025
Avg. Monthly Volume323 526
Avg. Quarterly Volume291 274

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

71%29%

Bearish Bullish

67%33%

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

There are no comments yet.

News

x